Salud financiera de hoja de balance de Median Technologies

Salud financiera controles de criterios 0/6

Median Technologies tiene un patrimonio de los accionistas total de €-21.9M y una deuda total de €30.4M, lo que sitúa su ratio deuda-patrimonio en -138.8%. Sus activos y pasivos totales son €32.9M y €54.8M respectivamente.

Información clave

-138.8%

Ratio deuda-patrimonio

€30.39m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	€16.10m
Patrimonio	-€21.90m
Total pasivo	€54.81m
Activos totales	€32.91m

Actualizaciones recientes sobre salud financiera

Is Median Technologies (EPA:ALMDT) Using Too Much Debt?

May 07

Recent updates

Revenues Tell The Story For Median Technologies SA (EPA:ALMDT) As Its Stock Soars 72%

Aug 30

Slammed 28% Median Technologies SA (EPA:ALMDT) Screens Well Here But There Might Be A Catch

Jun 30

Investors Give Median Technologies SA (EPA:ALMDT) Shares A 28% Hiding

Mar 14

Median Technologies SA (EPA:ALMDT) Looks Just Right With A 26% Price Jump

Jan 03

Newsflash: Median Technologies SA (EPA:ALMDT) Analysts Have Been Trimming Their Revenue Forecasts

Jul 14

Median Technologies SA (EPA:ALMDT) Might Not Be As Mispriced As It Looks After Plunging 46%

May 05

Is Median Technologies (EPA:ALMDT) Using Too Much Debt?

May 07

Announcing: Median Technologies (EPA:ALMDT) Stock Increased An Energizing 254% In The Last Year

Dec 28

Análisis de la situación financiera

Pasivos a corto plazo: ALMDT tiene patrimonio neto negativo. Es una situación más grave que activos a corto plazo que no cubren pasivos a corto plazo.

Pasivo a largo plazo: ALMDT tiene patrimonio neto negativo. Esta situación es más grave que el hecho de que los activos a corto plazo no cubran los pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: ALMDT tiene patrimonio negativo, una situación más grave que un alto nivel de endeudamiento.

Reducción de la deuda: ALMDT tiene patrimonio neto negativo, por lo que no necesitamos comprobar si su deuda se ha reducido con el tiempo.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: ALMDT tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: ALMDT tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 13.3% cada año

Salud financiera de hoja de balance de Median Technologies

Salud financiera controles de criterios 0/6

Información clave

Actualizaciones recientes sobre salud financiera

Is Median Technologies (EPA:ALMDT) Using Too Much Debt?

Recent updates

First half 2024 earnings released: €0.68 loss per share (vs €0.64 loss in 1H 2023)

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Median Technologies to Share Positive Pivotal Data for Eyonis LCS Diagnostic Software as Medical Device at the IASLC 2024 World Conference on Lung Cancer

Revenues Tell The Story For Median Technologies SA (EPA:ALMDT) As Its Stock Soars 72%

Median Technologies Announces Pivotal Reality Study of Its Eyonis™? Lcs Lung Cancer Diagnostic Met All Primary and Secondary Endpoints

Median Technologies SA to Report First Half, 2024 Results on Oct 24, 2024

Slammed 28% Median Technologies SA (EPA:ALMDT) Screens Well Here But There Might Be A Catch

Consensus EPS estimates fall by 15%

New major risk - Financial position

Consensus EPS estimates fall by 20%

Consensus EPS estimates fall by 20%, revenue upgraded

Median Technologies SA, Annual General Meeting, Jun 19, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Share price stability

Investors Give Median Technologies SA (EPA:ALMDT) Shares A 28% Hiding

Price target increased by 25% to €24.40

Median Technologies SA to Report Fiscal Year 2023 Results on Apr 25, 2024

Median Technologies SA (EPA:ALMDT) Looks Just Right With A 26% Price Jump

Price target decreased by 22% to €19.47

Median Technologies's iBiopsy HCC Detection AI Model Developed on the PHELICAR Clinical Data Registry, to Be Presented at the ESMO Congress

Median Technologies Appoints Ben Mcdonald to Its Board of Directors

Median Technologies SA, Annual General Meeting, Oct 10, 2023

Median Technologies SA to Report First Half, 2023 Results on Oct 19, 2023

Consensus revenue estimates fall by 12%

Newsflash: Median Technologies SA (EPA:ALMDT) Analysts Have Been Trimming Their Revenue Forecasts

Median Technologies SA announced that it expects to receive €10 million in funding from Lake Bridge Capital Inc

Price target decreased by 15% to €29.03

Median Technologies SA announced that it expects to receive €10 million in funding from Lake Bridge Capital Inc

New major risk - Financial position

Median Technologies SA, Annual General Meeting, Jun 20, 2023

Median Technologies SA (EPA:ALMDT) Might Not Be As Mispriced As It Looks After Plunging 46%

Full year 2022 earnings released: €1.28 loss per share (vs €1.25 loss in FY 2021)

Forecast to breakeven in 2025

Median Technologies SA to Report Fiscal Year 2022 Results on Apr 20, 2023

No independent directors

First half 2022 earnings released: €0.57 loss per share (vs €0.65 loss in 1H 2021)

Median Technologies Announces Formation of Clinical Advisory Board for Ibiopsy Lung Cancer Screening

Median Technologies SA to Report Q3, 2022 Results on Oct 20, 2022

Consensus EPS estimates fall by 16%

Median Technologies SA Launches Imaging Lab, Spearheading the Integration of iBiopsy® Artificial Intelligence Technologies Into iCRO Imaging Services for Oncology Trials

Median Technologies SA, Annual General Meeting, Jun 14, 2022

Is Median Technologies (EPA:ALMDT) Using Too Much Debt?

Full year 2021 earnings: EPS misses analyst expectations

No independent directors

Full year 2021 earnings: EPS misses analyst expectations

Median Technologies SA Files FDA 513(g) Regulatory Submission for iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device

Median Technologies Announces New Outstanding Performance for Its iBiopsy® Lung Cancer Screening CADx With a Focus on Stage 1 Lung Cancer Characterization

First half 2021 earnings released: €0.65 loss per share (vs €0.39 loss in 1H 2020)

Price target increased to €28.10

Price target increased to €28.10

Median Technologies SA announced that it has received €28.1 million in funding

Full year 2020 earnings released: €1.05 loss per share (vs €0.66 loss in FY 2019)

New 90-day high: €13.50

Median Technologies Appoints Thomas Bonnefont as Chief Operating and Commercial Officer

Median Technologies Sa Unveils New iBiopsy® Clinical Development Plan on Lung Cancer Screening

Median Technologies Inks Major Research Collaboration Agreement With the University of California San Diego

New 90-day high: €9.18

Announcing: Median Technologies (EPA:ALMDT) Stock Increased An Energizing 254% In The Last Year

Median Technologies Announces the Results of Preliminary Retrospective Study on the Evaluation of the Severity of Hepatic Fibrosis in Non-Alcoholic Steatohepatitis

First half earnings released

New 90-day high: €8.98

New 90-day high - €8.38

Median Technologies SA to Report First Half, 2020 Results on Oct 14, 2020

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera